These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21987440)

  • 1. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.
    Houlihan DD; Hopkins LJ; Suresh SX; Armstrong MJ; Newsome PN
    Hepatology; 2011 Nov; 54(5):1891-2; author reply 1892. PubMed ID: 21987440
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus mutants associated with hepatitis B surface antigen loss: chicken or egg?
    Tseng TC; Kao JH
    Hepatology; 2012 Feb; 55(2):656-7. PubMed ID: 21969004
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy.
    Jazayeri SM; Alavian SM
    Hepatology; 2011 Nov; 54(5):1889; author reply 1889-90. PubMed ID: 21898500
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
    Hsu CW; Yeh CT
    Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting treatment outcomes for HBV patients.
    AIDS Patient Care STDS; 2009 Mar; 23(3):223. PubMed ID: 19480059
    [No Abstract]   [Full Text] [Related]  

  • 6. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus.
    Shouval D
    J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
    [No Abstract]   [Full Text] [Related]  

  • 8. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
    Moucari R
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy of acute and fulminant hepatitis B.
    Tillmann HL; Patel K
    Intervirology; 2014; 57(3-4):181-8. PubMed ID: 25034486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.
    Rijckborst V; Hansen BE; Ferenci P; Brunetto MR; Tabak F; Cakaloglu Y; Lanza AG; Messina V; Iannacone C; Massetto B; Regep L; Colombo M; Janssen HLA; Lampertico P
    J Hepatol; 2012 May; 56(5):1006-1011. PubMed ID: 22245886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2012 Apr; 35(7):842-3; discussion 843-4. PubMed ID: 22404402
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response predictors to treatment with pegylated interferon in chronic hepatitis B.
    Ferreira PR; Tenore Sde B
    Braz J Infect Dis; 2010; 14(5):519-25. PubMed ID: 21221484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    Idilman R
    Turk J Gastroenterol; 2017 Sep; 28(5):412-416. PubMed ID: 28936972
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B virus genotypes: "clinical & therapeutic implications".
    Khawaja RA; Khawaja AA
    J Pak Med Assoc; 2009 Feb; 59(2):101-4. PubMed ID: 19260575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protocol for the antiviral therapy of hepatitis B and D].
    ; ; Gervain J; Horváth G; Hunyady B; Makara M; Pár A; Szalay F; Tornai I; Telegdy L
    Orv Hetil; 2010 Jan; 151(1):24-8. PubMed ID: 20031523
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.